|
|
What is new in Endocrinology?
1) Tirzepatide, a new incretin therapy in type 2 diabetes.
Weekly subcutaneous Tirzepatide,a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, was better than weekly subcutaneous Simaglutide in A1c lowering and weight reduction.
Frías JP, et al. New England Journal of Medicine June 25, 2021. DOI: 10.1056/NEJMoa2107519
2) FDA approves the first smart insulin pen system to help with dosing.
3) No evidence of an association between vitamin D and COVID-19.
A systematic review found no evidence of association between vitamin D levels and severity of symptoms or mortality due to COVID-19.
Grove A, et al. BMJ Open 2021;11(5):e043737
4) One-step or two-step screening strategy for gestational diabetes resulted in no difference in perinatal and maternal complications.
Despite more diagnoses of gestational diabetes with the one-step approach than with the two-step approach, there were no significant between-group differences in the risks of the primary outcomes relating to perinatal and maternal complications.
Hillier TA, et al. New England Journal of Medicine 2021; 384:895-904.
5) Imeglimin, a novel glucose-lowering agent, is effective and safe for patients with type 2 diabetes.
Imeglimin works by improving mitochondrial function to enhance insulin sensitivity and glucose-mediated insulin secretion. In a phase 3 trial, the drug lowered HbA1c by 0.87% compared to placebo and adverse events were comparable to placebo.
Dubourg J, et al. Diabetes Care 2021;44(4): 952-959.1
6) Glucose-lowering medications do not have significant impact on COVID-19 mortality risk in people with type 2 diabetes.
In the context of the COVID-19 pandemic, there is no clear indication to change prescribing of glucose-lowering drugs in people with type 2 diabetes.
Khunti K, et al. Lancet 2021;9(5):293-303.
Weekly subcutaneous Tirzepatide,a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, was better than weekly subcutaneous Simaglutide in A1c lowering and weight reduction.
Frías JP, et al. New England Journal of Medicine June 25, 2021. DOI: 10.1056/NEJMoa2107519
2) FDA approves the first smart insulin pen system to help with dosing.
3) No evidence of an association between vitamin D and COVID-19.
A systematic review found no evidence of association between vitamin D levels and severity of symptoms or mortality due to COVID-19.
Grove A, et al. BMJ Open 2021;11(5):e043737
4) One-step or two-step screening strategy for gestational diabetes resulted in no difference in perinatal and maternal complications.
Despite more diagnoses of gestational diabetes with the one-step approach than with the two-step approach, there were no significant between-group differences in the risks of the primary outcomes relating to perinatal and maternal complications.
Hillier TA, et al. New England Journal of Medicine 2021; 384:895-904.
5) Imeglimin, a novel glucose-lowering agent, is effective and safe for patients with type 2 diabetes.
Imeglimin works by improving mitochondrial function to enhance insulin sensitivity and glucose-mediated insulin secretion. In a phase 3 trial, the drug lowered HbA1c by 0.87% compared to placebo and adverse events were comparable to placebo.
Dubourg J, et al. Diabetes Care 2021;44(4): 952-959.1
6) Glucose-lowering medications do not have significant impact on COVID-19 mortality risk in people with type 2 diabetes.
In the context of the COVID-19 pandemic, there is no clear indication to change prescribing of glucose-lowering drugs in people with type 2 diabetes.
Khunti K, et al. Lancet 2021;9(5):293-303.